Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 1:13 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1993–2016 of 2,516 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Sequence Clear all

Conditions: Parkinson Disease
Interventions: carbidopa/levodopa, as prescribed by treating physician; Drug
Lead sponsor: University of Michigan; Other
Eligibility: 45 Years to 90 Years
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Atopic Dermatitis
Interventions: PF-08049820, Midazolam, Dabigatran Etexilate, Portia (EE and LN) or equivalent oral tablet; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Acid Base Disorder
Interventions: Targeted genomic sequencing; Diagnostic Test
Lead sponsor: Sharp HealthCare; Other
Eligibility: 1 Day to 6 Months
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: San Diego, California

Conditions: Breast Tumors
Interventions: Not listed
Lead sponsor: State University of New York - Upstate Medical University; Other
Eligibility: 18 Years to 70 Years · Female only
Enrollment: 3 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2015
U.S. locations: 1
States / cities: Syracuse, New York

Conditions: Visual Acuity
Interventions: Test Lens; Device
Lead sponsor: Johnson & Johnson Vision Care, Inc.; Industry
Eligibility: 40 Years to 70 Years
Enrollment: 102 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 5
States / cities: Jacksonville, Florida • Longwood, Florida • Maitland, Florida + 2 more

Conditions: Infection, Human Immunodeficiency Virus, HIV Infections
Interventions: GSK2838232 100 mg tablet, GSK2838232 50 mg capsule, Ritonavir 100 mg tablets, Placebo for GSK2838232 tablets; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 26 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Healthy Participants
Interventions: PF-07321332/ritonavir, Ritonavir; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Epilepsy
Interventions: Retigabine / Ezogabine; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Arthritis, Rheumatoid
Interventions: CP-690,550, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 795 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 46
States / cities: Huntsville, Alabama • Jonesboro, Arkansas • Palo Alto, California + 41 more

Conditions: Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma
Interventions: Pembrolizumab, Stereotactic Body Radiation Therapy (5 days), Surgical Resection; Drug · Radiation · Procedure
Lead sponsor: Providence Health & Services; Other
Eligibility: 18 Years and older
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2031
U.S. locations: 3
States / cities: San Diego, California • Portland, Oregon

Conditions: Systemic Lupus Erythematosus (SLE)
Interventions: Placebo, Dapirolizumab pegol (DZP); Drug
Lead sponsor: UCB Biopharma S.P.R.L.; Industry
Eligibility: 18 Years and older
Enrollment: 182 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 25
States / cities: Birmingham, Alabama • El Cajon, California • Huntington Beach, California + 21 more

Conditions: Overactive Bladder (OAB)
Interventions: Mirabegron, Tolterodine ER; Drug
Lead sponsor: Astellas Pharma Global Development, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 376 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 22
States / cities: Homewood, Alabama • Anchorage, Alaska • Tucson, Arizona + 19 more

Conditions: Healthy Participants
Interventions: Divarasib, Itraconazole; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: HIV Infections
Interventions: Conventional dolutegravir 10 mg tablet, Conventional dolutegravir 50 mg tablet, Dispersible dolutegravir 5 mg tablet, Conventional dolutegravir 25 mg tablet; Drug
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 38 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Aqueous Deficient Dry Eye, Meibomium Gland Dysfunction
Interventions: Subjective Questionnaire, Measurement with wavefront sensor (right eye, then left eye), Instill Saline Drop; Behavioral · Procedure · Drug
Lead sponsor: University of Rochester; Other
Eligibility: 20 Years to 65 Years
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Hypoxic Pulmonary Vasoconstriction
Interventions: iloprost; Drug
Lead sponsor: Loma Linda University; Other
Eligibility: 18 Years to 80 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008
U.S. locations: 1
States / cities: Loma Linda, California

Conditions: Crohn Disease
Interventions: Radiotracer Injection, Contrast Media, Magnetic Resonance, Blood Draw, Glucagon, Imaging, Oral contrast media application; Drug · Diagnostic Test
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 99 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 1
States / cities: Charlestown, Massachusetts

Conditions: Covid19, Acute Respiratory Distress Syndrome, Bacterial Sepsis, Bacterial Infections
Interventions: BVA-100, Transpulmonary Thermodilution (TPTD), Sublingual Microcirculation; Device
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years to 95 Years
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 3
States / cities: Bethesda, Maryland • New York, New York • Winston-Salem, North Carolina

Conditions: Healthy Volunteers
Interventions: verapamil; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 79 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Healthy
Interventions: Mifepristone; Drug
Lead sponsor: Corcept Therapeutics; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Cancer
Interventions: GSK1120212; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 2
States / cities: San Antonio, Texas • Salt Lake City, Utah

Conditions: Focal Segmental Glomerulosclerosis (FSGS)
Interventions: VX-147; Drug
Lead sponsor: Vertex Pharmaceuticals Incorporated; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 21 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Healthy
Interventions: ZTlido (Lidocaine Topical System) 1.8%, Salonpas (Lidocaine Patch 4%), Aspercreme (Lidocaine Patch 4%), IcyHot (Lidocaine 4% + Menthol 1% Patch); Drug
Lead sponsor: Scilex Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 1
States / cities: Dilworth, Minnesota

Conditions: Post Traumatic Stress Disorder
Interventions: Very Brief Exposure to Combat Images; Other
Lead sponsor: Children's Hospital Los Angeles; Other
Eligibility: 18 Years to 50 Years
Enrollment: 90 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Los Angeles, California

Search by objective public record fields.

Vigor and the LDR in Parkinson Disease

A Study to Learn If the Study Medicine Called PF-08049820 Changes How the Body Processes the Other Study Medicines Called Oral Contraceptives, Midazolam, and Dabigatran in Healthy Adult Female Participants

Rapid Diagnostics for Genetic Disorders in Neonates

Evaluate the Use of the Magnetic Resonance Spectroscopy in Determining if the Breast Tumor is Benign or Malignant

Evaluation of Rotation With a Multifocal Toric Contact Lens

A Two-part Study to Compare a Tablet and Capsule Formulation of GSK2838232 With and Without Food, and to Assess the Safety and Drug Levels of Repeated Once-daily Doses of GSK2838232 Without Ritonavir

Food Effect Study to Evaluate the Effect of High-Fat Meal on the Relative Bioavailability of PF-07321332 Boosted With Ritonavir in Healthy Adult Participants

Effect of Haemodialysis on the Pharmacokinetics of Ezogabine/Retigabine and Its N-acetyl Metabolite

A Study Comparing 2 Doses Of CP-690,550 Vs. Placebo For The Treatment Of Rheumatoid Arthritis In Patients On Other Background Arthritis Medications

Neoadjuvant Immunoradiotherapy in Head & Neck Cancer (NIRT 2-HNC)

A Phase 2 Efficacy and Safety Study of Dapirolizumab Pegol (DZP) in Systemic Lupus Erythematosus

A Study to Evaluate Tolerability and Participants Preference Between Mirabegron and Tolterodine Extended Release (ER) in Participants With Overactive Bladder (OAB)

A Study to Determine the Effect of Itraconazole on the Pharmacokinetics of Divarasib in Healthy Participants

Bioavailability Study of 10 Milligram (mg) and 5 mg Tablets Versus Conventional Tablets of Dolutegravir

Non-invasive Tear Film Dynamic Measurements in Normal, MGD and ADDE Subjects After Saline Instillation

Effects of Iloprost on Hypoxic Pulmonary Vasoconstriction at Altitude

Value of PET/MR Enterography in the Assessment of Crohn's Disease Using a Collagen-binding Radiotracer.

Blood Volume Assessment in COVID-19 and Bacterial Sepsis

Bioequivalence Study Of Verapamil

Crossover Drug-Drug Interaction Study to Determine Effects of Cytochrome P450 3A on Exposure to Mifepristone and Its Metabolites

A Study to Look at the Electrical Activity of the Heart in Subjects With Solid Tumor Cancers, Before and After Receiving the Study Treatment, GSK1120212

A Study Evaluating the Relative Bioavailability and Food Effect of a Tablet Formulation of VX-147

Clinical Adhesion Study Between ZTlido 1.8% and Three Over-the-counter External Analgesic Lidocaine-containing Patches

The Effects of Very Brief Exposure on PTSD in U.S. Combat Veterans